Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors: A Meta-Analysis of Original Data From 7 Randomized Controlled Trials
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
BACKGROUND: Although it is widely believed that the various classes of antidepressants are equally effective, clinically meaningful differences may be obscured in individual studies because of a lack of statistical power. The present report describes a meta-analysis of original data from a complete set of studies comparing the norepinephrine/dopamine reuptake inhibitor (NDRI) bupropion with selective serotonin reuptake inhibitors (SSRIs; sertraline, fluoxetine, or paroxetine). METHOD: Individual patient data were pooled from a complete set of 7 randomized, double-blind studies comparing bupropion (N = 732) with SSRIs (fluoxetine, N = 339; sertraline, N = 343; paroxetine, N = 49) in outpatients with major depressive disorder (DSM-III-R or DSM-IV); 4 studies included placebo (N = 512). Response and remission rates were compared at week 8 or endpoint in both the intent-to-treat sample, using the last-observation-carried-forward (LOCF) method to account for attrition, and the observed cases. Tolerability data, including incidence of sexual side effects, were also compared. RESULTS: The LOCF response and remission rates for the bupropion (62% and 47%) and SSRI (63% and 47%) groups were similar; both active therapies were superior to placebo (51% and 36%; all comparisons, p < .001). The same pattern of results was demonstrated on the observed cases analyses. Although bupropion and SSRIs were generally well tolerated, SSRI therapy resulted in significantly higher rates of sexual side effects as compared to both bupropion and placebo. SSRIs were also associated with more somnolence and diarrhea, and bupropion was associated with more dry mouth. CONCLUSION: Bupropion and the SSRIs were equivalently effective and, overall, both treatments were well tolerated. The principal difference between these treatments was that sexual dysfunction commonly complicated SSRI therapy, whereas treatment with bupropion caused no more sexual dysfunction than placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, SSRIs and other traditional antidepressants are problematic as they typically take weeks before therapeutic effects are observed and require daily administration”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Thase et al., 2005
In the citing paper
“Particularly relevant in the present context are previous reports [290,296,297] that although both DA and non-DA agents can be used to effectively treat mood disorders, DA agents generally have superior effects on symptoms of anhedonia, specifically when compared with non-DA agents [19,298-300].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [290]
In the citing paper
“Bupropion, a DA and norepinephrine reuptake inhibitor, is an effective antidepressant [290] that seems to specifically increase feelings of positive affect [291].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [290]
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 310
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-160 · Cited by 51
The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
Moreira, R. (2011) · Clinical Drug Investigation · doi:10.2165/1159616-s0-000000000-00000 · Cited by 55
Battle, C. L., Uebelacker, L., Friedman, M. A., Cardemil, E. V., Beevers, C. G., & Miller, I. W. (2010) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000390763.57946.93 · Cited by 50
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Universal Depression Screening, Diagnosis, Management, and Outcomes at a Student-Run Free Clinic
Soltani, M., Smith, S. D., Beck, E., & Johnson, M. L. (2014) · Academic Psychiatry · doi:10.1007/s40596-014-0257-x · Cited by 49
Analysis of 34 candidate genes in bupropion and placebo remission
Tiwari, A. K., Zai, C. C. H., Sajeev, G., Arenovich, T., Müller, D. J., & Kennedy, J. L. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000843 · Cited by 45
Bipolar depression: Diagnostic and treatment considerations
Thase, M. E. (2006) · Development and Psychopathology · doi:10.1017/s0954579406060585 · Cited by 52
Self-citationImaging predictors of remission to anti-depressant medications in major depressive disorder
Kee, F., Korgaonkar, M. S., & Grieve, S. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.002 · Cited by 49
Cutler, J. A., Rush, A. J., McMahon, F. J., & Laje, G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111434622 · Cited by 44
Antidepressant pharmacogenetics
Singh, A., Bousman, C., Ng, C. H., & Berk, M. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000023 · Cited by 47
Unützer, J., Carlo, A. D., Arao, R. F., Vredevoogd, M. A., Fortney, J. C., Powers, D., & Russo, J. E. (2020) · Health Affairs · doi:10.1377/hlthaff.2019.01714 · Cited by 45
Demitrack, M. A., & E.Thase, M. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4312 · Cited by 43
Self-citationA Systematic Review of Pharmacological Treatments for Internet Gaming Disorder
de Sá, R. R. C., Coelho, S. G., Parmar, P. K., Johnstone, S., Kim, H. S. A., & Tavares, H. (2023) · Psychiatry Investigation · doi:10.30773/pi.2022.0297 · Cited by 50
Xu, S., Zhou, Z. Q., Li, X. M., Ji, M. H., Zhang, G. F., & Yang, J. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.07.032 · Cited by 44
Serretti, A., Olgiati, P., Bajo, E., Bigelli, M., & De Ronchi, D. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.572998 · Cited by 42
Antidepressant drug development: Focus on triple monoamine reuptake inhibition
Lane, R. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114553252 · Cited by 44
Patient and Clinician Perceptions of Therapeutic Alliance as Predictors of Improvement in Depression
Bolle, M. D., Johnson, J. G., & Fruyt, F. D. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000320895 · Cited by 50
Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response
Ji, Y., Biernacka, J. M., Snyder, K., Drews, M., Pelleymounter, L. L., Colby, C., Wang, L., Mrazek, D. A., & Weinshilboum, R. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.69 · Cited by 43
Bupropion in the Treatment of Outpatients with Asthma and Major Depressive Disorder
Brown, E. S., Vornik, L. A., Khan, D. A., & Rush, A. J. (2007) · The International Journal of Psychiatry in Medicine · doi:10.2190/d235-2285-2121-6724 · Cited by 40
Limitations of contemporary antidepressants: tolerability.
Papakostas, G. I. (2007) · PubMed · Cited by 44
Nakajima, S., Uchida, H., Suzuki, T., Watanabe, K., Hirano, J., Yagihashi, T., Takeuchi, H., Abe, T., Kashima, H., & Mimura, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.008 · Cited by 40
Rosenquist, P. B., Krystal, A. D., Heart, K. L., Demitrack, M. A., & McCall, W. V. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.011 · Cited by 42
Hypersomnia in Mood Disorders: a Rapidly Changing Landscape
Plante, D. T. (2015) · Current Sleep Medicine Reports · doi:10.1007/s40675-015-0017-9 · Cited by 41
Burstein, O., Franko, M., Gale, E., Handelsman, A., Barak, S., Motsan, S., Shamir, A., Toledano, R., Simhon, O., Hirshler, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188043 · Cited by 39
Pharmacotherapy of bipolar depression: An update
Thase, M. E. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0055-6 · Cited by 42
Self-citationStereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo
Gufford, B. T., Lu, J. B. L., Metzger, I. F., Jones, D. R., & Desta, Z. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.068908 · Cited by 39
Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder
Rethorst, C. D., South, C. C., Rush, A. J., Greer, T. L., & Trivedi, M. H. (2017) · Depression and Anxiety · doi:10.1002/da.22670 · Cited by 35
Antipsychotics as antidepressants
Roberts, R. J., Lohano, K., & El‐Mallakh, R. S. (2015) · Asia-Pacific Psychiatry · doi:10.1111/appy.12186 · Cited by 41
Eisendrath, S. J., Gillung, E., Delucchi, K., Mathalon, D. H., Yang, T. T., Satre, D. D., Rosser, R., Sipe, W. E. B., & Wolkowitz, O. M. (2015) · Mindfulness · doi:10.1007/s12671-014-0280-8 · Cited by 34
“Moreover, there are well-documented problems with antidepressant adherence, side effects, drug interactions, cost, and personal preference (Thase et al., 2005).”
BackgroundRapid antidepressant effects: moving right along
Martinowich, K., Jimenez, D. V., Zarate, C. A., & Manji, H. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.55 · Cited by 32
Rethorst, C. D., Tu, J., Carmody, T. J., Greer, T. L., & Trivedi, M. H. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.01.052 · Cited by 33
Kato, M., Zanardi, R., Rossini, D., Ronchi, D. D., Okugawa, G., Kinoshita, T., Colombo, C., & Serretti, A. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2007.12.012 · Cited by 34
Safety Considerations in Drug Treatment of Depression in HIV-Positive Patients: An Updated Review
Watkins, C. C., Pieper, A. A., & Treisman, G. J. (2011) · Drug Safety · doi:10.2165/11592070-000000000-00000 · Cited by 37
Masters, A. R., Gufford, B. T., Lu, J. B. L., Metzger, I. F., Jones, D. R., & Desta, Z. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232876 · Cited by 35
Papakostas, G. I., Kornstein, S. G., Clayton, A. H., Soares, C. N., Hallett, L. A., Krishen, A., & Tucker, V. L. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8400 · Cited by 35
Shelton, R. C., Parikh, S. V., Law, R. A., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Macaluso, M., et al. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113017 · Cited by 31
Self-citationWang, Y., Liu, X., Yu, Y., Han, Y., Wei, J., Collier, D. A., Li, T., & Ma, X. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.06.024 · Cited by 31
Self-citationRepeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects
Zhang, G.-F., Liu, W.-X., Qiu, L.-L., Guo, J., Wang, X.-M., Sun, H., Yang, J., & Zhou, Z. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2014.11.007 · Cited by 32
Psychological Issues in Adults with Type 2 Diabetes
Gonzalez, J. S., Esbitt, S. A., Schneider, H. E., Osborne, P. J., & Kupperman, E. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0029-6_2 · Cited by 41
Zhang, Y., Li, Y., Chen, X., Chen, X., Chen, C., Wang, L., Xu, D., Wang, G., Gu, R., Li, F. Y., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00677 · Cited by 29
Dunn, J. D., Cannon, E., Mitchell, M. P., & Curtiss, F. R. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.4.294 · Cited by 29
Holubová, K., Nekovářová, T., Pistovčáková, J., Šulcová, A., Stuchlík, A. (., & Valeš, K. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00130 · Cited by 29
Calandra, C., Russo, R. G., & Luca, M. (2011) · Psychiatric Quarterly · doi:10.1007/s11126-011-9192-0 · Cited by 30
Bi, Y., Ren, D., Guo, Z., Ma, G., Xu, F., Chen, Z., An, L. K., Zhang, N., Ji, L., Yuan, F., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110036 · Cited by 30
Owolabi, R. A., Akanmu, M. A., & Adeyemi, O. I. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.01.015 · Cited by 28
Kochanowska-Karamyan, A. J., ARAÚJO, H. C., Zhang, X., El‐Alfy, A. T., de Carvalho, P. B., Avery, M. A., Holmbo, S. D., Magolan, J., & Hamann, M. T. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01107 · Cited by 27
Cabanero, M., Laje, G., Detera-Wadleigh, S., & Mcmahon, F. (2009) · Pharmacogenetics & Genomics · doi:10.1097/fpc.0b013e328320a3e2 · Cited by 28
Desvenlafaxine: Another “Me Too” Drug?
Sopko, M. A., Ehret, M. J., & Grgas, M. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k563 · Cited by 27
Emerging treatments for depression
Holtzheimer, P. E., & Nemeroff, C. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.17.2323 · Cited by 32
Whooley, M. A. (2012) · JAMA · doi:10.1001/jama.2012.3466 · Cited by 26
Clayton, A. H., Baker, R. A., Sheehan, J. J., Cain, Z., Forbes, R. A., Marler, S. V., Marcus, R. N., Berman, R., & Thase, M. E. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-459 · Cited by 27
Self-citationJastrzębska, K., Walczak, M., Cieślak, P. E., Szumiec, Ł., Turbasa, M., Engblom, D., Błasiak, T., & Parkitna, J. M. R. (2016) · Scientific Reports · doi:10.1038/srep37171 · Cited by 27
Spotlight on Bupropion in Major Depressive Disorder???
Dhillon, S., Yang, L. P. H., & Curran, M. P. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00006 · Cited by 26
Sun, X., Li, X., He, L., He, G., Yu, T., & Dong, Z. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s93562 · Cited by 24
For whom does interpersonal psychotherapy work? A systematic review
Bernecker, S. L., Coyne, A. E., Constantino, M. J., & Ravitz, P. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.07.001 · Cited by 28
Li, A., & Meyre, D. (2014) · Current Psychiatry Reviews · doi:10.2174/1573400510666140630170549 · Cited by 28
Aberrant amino acid transport in fibroblasts from patients with bipolar disorder
Persson, M., Johansson, J., Vumma, R., Raita, J., Bjerkenstedt, L., Wiesel, F. ‐., & Venizelos, N. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.095 · Cited by 23
Sobel, M. E., Madigan, D., & Wang, W. (2016) · Psychometrika · doi:10.1007/s11336-016-9507-z · Cited by 26
Pharmacotherapy of personality disorders
Triebwasser, J., & Siever, L. J. (2007) · Journal of Mental Health · doi:10.1080/09638230601182078 · Cited by 26
Maneeton, B., Maneeton, N., Eurviriyanukul, & Srisurapanont, M. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46849 · Cited by 27
Mohamed, S., Johnson, G. R., Vertrees, J. E., Guarino, P., Weingart, K. R., Young, I. T., Yoon, J., Gleason, T., Kirkwood, K. A., Kilbourne, A. M., et al. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.08.005 · Cited by 23
Stang, P., Suppapanaya, N., Hogue, S., Park, D., & Rigney, U. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31802b59e4 · Cited by 22
Cerebral MAO Activity Is Not Altered by a Novel Herbal Antidepressant Treatment
Doron, R., Versano, Z., Burstein, O., Franko, M., Shamir, A., Toledano, R., Handelsman, A., & Rehavi, M. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01366-0 · Cited by 22
Liou, Y., Chen, C.-H., Cheng, C.-Y., Chen, S., Chen, T., Yu, Y. W. ‐., Nian, F., Tsai, S., & Hong, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032984 · Cited by 20
Lekman, M., Paddock, S., & McMahon, F. J. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256297 · Cited by 21
Ginsberg, L. D. (2009) · CNS Spectrums · doi:10.1017/s1092852900026353 · Cited by 19
Tafseer, S., Gupta, R., Ahmad, R. S., Jain, S., Bhatia, M. S., & Gupta, L. K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173073 · Cited by 19
Clarke, J., Skoufalos, A., Medalia, A., & Fendrick, A. (2016) · Population health management · doi:10.1089/pop.2016.0114 · Cited by 15
Amsterdam, J. D., Lorenzo‐Luaces, L., & DeRubeis, R. J. (2016) · Bipolar Disorders · doi:10.1111/bdi.12442 · Cited by 18
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Cubała, W. J., Bajbouj, M., Bauer, M., Baune, B. T., Cardoner, N., Devlin, F., Doolin, K., Herrero, R. D., Elices, M., Feeney, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0096 · Cited by 20
Self-citationSidi, H., Asmidar, D., Hod, R., & Ng, C. G. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02256.x · Cited by 18
N. Fountoulakis, K., S. McIntyre, R., & F. Carvalho, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630174343 · Cited by 15
Drug Class Review: Second-Generation Antidepressants
Gartlehner, G., Hansen, R. A., Reichenpfader, U., Kaminski, A., Kien, C., Strobelberger, M., Noord, M. V., Thieda, P., Thaler, K. J., & Gaynes, B. N. (2011) · Cited by 17
Bupropion extended-release for depressive disorders
Jefferson, J. W. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.715 · Cited by 18
Hines, L. J., Wilke, R. A., Myers, R. A., Mathews, C. A., Liu, M., Baye, J. F., Petry, N., Cicali, E. J., Duong, B. Q., Elwood, E. N., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13822 · Cited by 17
Efficacy of transcutaneous vagus nerve stimulation as treatment for depression: A systematic review
Guerriero, G., Wartenberg, C., Bernhardsson, S., Gunnarsson, S., Ioannou, M., Liljedahl, S., Magnusson, K., Svanberg, T., & Steingrímsson, S. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100233 · Cited by 18
Parikh, S. V., Law, R. A., Hain, D. T., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Forester, B. P., Shelton, R. C., Macaluso, M., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114354 · Cited by 15
Self-citationKobayashi, Y., Koshino, Bahk, W.-M., & Sakai (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s48158 · Cited by 6
(2017) · Biomedical Research-tokyo · Cited by 15
Luft, M. J., Dobson, E. T., Levine, A. A., Croarkin, P. E., & Strawn, J. R. (2021) · CNS Spectrums · doi:10.1017/s1092852921000377 · Cited by 15
Exposure of mice to long-light: A new animal model to study depression
Becker, A., Bilkei‐Gorzó, A., Michel, K., & Zimmer, A. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.009 · Cited by 21
Peters, E. M., Balbuena, L., & Lodhi, R. J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.066 · Cited by 13
Psychiatric Pharmacogenomics in Pediatric Psychopharmacology
Wall, C. A., Croarkin, P. E., Swintak, C. C., & Koplin, B. A. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.001 · Cited by 13
Chronic venlafaxine treatment fails to alter the levels of galanin system transcripts in normal rats
Petschner, P., Juhász, G., Tamási, V., Ádori, C., Tóthfalusi, L., Hökfelt, T. G. M., & Bagdy, G. (2016) · Neuropeptides · doi:10.1016/j.npep.2016.01.010 · Cited by 12
A Bibliometric Analysis of Research on Ketamine From 2001 to 2020
Miao, H., Yu, K., Gao, D., Lin, X., Cao, Y., Liu, X., Qiao, H., & Li, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.839198 · Cited by 13
Kavanagh, B. E., Williams, L. J., Berk, M., Turner, A., Jackson, H. J., Mohebbi, M., Kanchanatawan, B., Ashton, M. M., Ng, C. H., Maes, M. H. J., et al. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2018-0308 · Cited by 12
Bupropion: efficacy and safety in the treatment of depression.
Ruiz, J. S., Gibert, J., Fraile, M., Bobes, J., Vallejo, J., Iglesias, C., & Iriarte, V. (2011) · Actas Españolas de Psiquiatría · Cited by 12
Zeng, Q.-B., Huang, X., Xu, R., Shang, D., Huang, S., Huang, X., Yang, X.-H., Balbuena, L., Xiang, Y., & Zheng, W. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.041 · Cited by 10
Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression
Atake, K., Hori, H., Kageyama, Y., Koshikawa, Y., Igata, R., Tominaga, H., Katsuki, A., Bando, H., Sakai, S., Nishida, K., et al. (2022) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2045354 · Cited by 12
Briggs, L., & Macleod, S. (2010) · Griffith Research Online · Cited by 12
Segura‐Garcìa, C., Rania, M., Carbone, E. A., de Filippis, R., Aloi, M., Caroleo, M., Grasso, G., Calabrò, G., Fazia, G., Staltari, F. A., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.635502 · Cited by 10
Stevens, E. B., Wolfman, W., Hernández-Galán, L., & Shea, A. K. (2024) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002309 · Cited by 10
Murata, Y., Kamishioiri, Y., Tanaka, K. F., Sugimoto, H., Sakamoto, S., Kobayashi, D., & Mine, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.040 · Cited by 11
Højgaard, K., Christiansen, S. L., Bouzinova, E. V., & Wiborg, O. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4781-8 · Cited by 9
Застрожин, М. С., Skryabin, V. Y., Sorokin, A., Buzik, O. Z., Александровна, Б. И., Гришина, Е. А., Ryzhikova, K., Шипицын, В. В., Bryun, E. A., & Sychev, D. A. (2020) · Drug metabolism and drug interactions · doi:10.1515/dmpt-2019-0033 · Cited by 9
Bamfo, N. O., Lu, J. B. L., & Desta, Z. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000867 · Cited by 9
Moreno-Coutiño, A. B., & icaza, M. E. T. M. M. (2008) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 19
Mosca, D., Zhang, M., Prieto, R., & Boucher, M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000674 · Cited by 10
Does Bupropion Impact More than Mood? A Case Report and Review of the Literature
Yasin, W., Ahmed, S. I., & Gouthro, R. V. (2019) · Cureus · doi:10.7759/cureus.4277 · Cited by 9
Fresh approaches to antidepressant drug discovery
Anacker, C. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.892071 · Cited by 9
Metadata
- Authors
- Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y.
- Affiliations
- University of Pittsburgh Medical Center (US)
- GlaxoSmithKline (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-08-15
- Volume
- 66
- Issue
- 08
- Pages
- 974-981
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2089694151
- Cited by
- 304
- References
- 0
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 13 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 10 · 2017: 15 · 2016: 18 · 2015: 10 · 2014: 20 · 2013: 18 · 2012: 23
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH30915)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- bupropion, selective serotonin reuptake inhibitors, major depressive disorder, antidepressant efficacy, remission rate, sexual dysfunction, drug tolerability, fluoxetine, sertraline, paroxetine, norepinephrine-dopamine reuptake inhibitors, placebo comparison
- MeSH terms
- Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Bupropion, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.